Group 1 - Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, fulfilling obligations under the Option Agreement, resulting in total returns of $118 million on a $99.5 million investment [1][2] - Oramed retains a $27 million note and a $12 million convertible note with Scilex, convertible into equity at $36 per share, with repayment scheduled through October 2026 if not converted [2] - The Board of Directors approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, funded by surplus capital [3] Group 2 - Oramed is a clinical-stage pharmaceutical company focused on oral delivery solutions for injectable drugs, utilizing its Protein Oral Delivery (POD™) technology [4]

Core Insights - Oramed Pharmaceuticals Inc. reported a strong financial performance for the nine months ended September 30, 2025, with total assets increasing by 42% to $220.5 million [1][7] - The company achieved a net income of $65 million, a significant turnaround from a net loss of $6.1 million in the same period last year, primarily due to cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. [3][4][7] Financial Highlights - Net income (pre-tax) reached $65.0 million, compared to a net loss of $6.1 million in the same period last year [7] - The company completed a full repayment from Scilex, receiving approximately $27 million during the period, totaling $100 million in principal return from this strategic investment [4][7] - Basic earnings per share were reported at $1.30, while diluted earnings per share were $1.26 [7] - Total assets grew from $155.3 million to $220.5 million year-over-year, marking a 42% increase [7] - Research and Development (R&D) expenses decreased from $4.9 million to $4.4 million, while General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million [7] Management Commentary - CEO Nadav Kidron emphasized that the disciplined investment strategy is yielding strong results, providing the company with greater financial flexibility to pursue strategic opportunities while advancing its oral drug delivery platform [4]

Core Viewpoint - Oramed Pharmaceuticals Inc. has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, ensuring fair treatment and enhancing negotiation power with potential acquirers [1][3]. Group 1: Rights Agreement Details - The Rights Agreement, effective November 17, 2025, grants stockholders one common stock purchase right for each share held, aimed at preventing unfair takeover tactics [1][2]. - Each Right allows stockholders to purchase one share of Common Stock at a price of $10.00, becoming exercisable if a person or group acquires 15% or more of the outstanding shares [2][3]. - The Rights will expire three years after adoption unless redeemed or exchanged earlier by the Company [4]. Group 2: Rights Exercise and Redemption - Upon triggering the ownership threshold, each Right can be exercised for shares or equivalent value, but Rights held by the triggering person will become void [3]. - The Board of Directors retains the option to redeem the Rights at $0.012 per Right before any person becomes an Acquiring Person [2][3]. Group 3: Dividend Distribution - The dividend distribution of the Rights will be payable on November 27, 2025, to stockholders of record as of the close of business on that date [4]. - The distribution of Rights is not taxable to stockholders [4]. Group 4: Company Overview - Oramed Pharmaceuticals Inc. is a pioneer in oral delivery solutions for drugs typically administered via injection, utilizing its Protein Oral Delivery (POD™) technology to enhance drug absorption [5].

Core Insights - Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, acquiring approximately 14.1 million shares at a price of $2.612 per share, aimed at supporting Alpha Tau's innovative cancer therapy technology [1][2] - The partnership combines Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology, enhancing both companies' capabilities in therapeutic delivery [1][3] - Oramed will provide strategic guidance and capital markets expertise to Alpha Tau through a three-year service agreement, which includes appointing two directors to Alpha Tau's Board [2][3] Company Overview - Oramed Pharmaceuticals specializes in oral delivery solutions for drugs typically administered via injection, utilizing its proprietary Protein Oral Delivery (POD™) technology to enhance drug integrity and absorption [4] - Alpha Tau Medical, founded in 2016, focuses on the research and development of the Alpha DaRT® technology for treating solid tumors, initially developed by professors from Tel Aviv University [5] Strategic Goals - The collaboration is expected to accelerate Alpha Tau's clinical trials across four indications in the U.S., expand manufacturing capacity, and enhance commercialization efforts [1][2] - Both companies share a vision of transforming therapeutic delivery methods, with Oramed focusing on oral administration and Alpha Tau on targeted radiation therapy [3]